Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia by Dunayevich, Eduardo, MD, Buchanan, Robert W, MD, Chen, Chao-Yin, PhD, Yang, Jun, PhD, Nilsen, Jon, PhD, Dietrich, Julie M, MS, Sun, Hong, MD, PhD, Marder, Stephen, MD

Get full text

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial by Németh, György, Dr, Laszlovszky, István, PharmD, Czobor, Pál, PhD, Szalai, Erzsébet, MD, Szatmári, Balázs, MD, Harsányi, Judit, MD, Barabássy, Ágota, MD, Debelle, Marc, MD, Durgam, Suresh, MD, Bitter, István, Prof, Marder, Stephen, Prof, Fleischhacker, W Wolfgang, Prof

Get full text

The Excited-State Lifetime of Poly(NDI2OD-T2) Is Intrinsically Short by Gish, Melissa K., Karunasena, Chamikara D., Carr, Joshua M., Kopcha, William P., Greenaway, Ann L., Mohapatra, Aiswarya Abhisek, Zhang, Junxiang, Basu, Aniruddha, Brosius, Victor, Pratik, Saied Md, Bredas, Jean-Luc, Coropceanu, Veaceslav, Barlow, Stephen, Marder, Seth R., Ferguson, Andrew J., Reid, Obadiah G.

Get full text